Perspective Therapeutics, Inc.
CATXAMEXHealthcare● Active
$2.93
$-0.11(-3.47%)
Market Cap$225956250
P/E Ratio—
52W High$6.16
52W Low$1.96
Perspective Therapeutics, Inc. (CATX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CATX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.25
Est. -$0.29 · +13.8%
Revenue
$0.00B
Est. $0.00B · -51.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
CATX reports quarterly as a AMEX-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.27 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.29 | -$0.25 | +13.8% | $0.00B | $0.00B | -51.7% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.37 | -$0.51 | -37.8% | $0.00B | $0.00B | -81.5% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.33 | -$0.35 | -6.1% | $0.00B | $0.00B | -10.1% |
| — Q3 FY2025 | Aug 13, 2025 | -$0.30 | -$0.30 | +0.0% | $0.00B | $0.00B | +34.0% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.28 | -$0.25 | +10.7% | $0.00B | $0.00B | +84.0% |
| ▲ Q1 FY2025 | Mar 26, 2025 | -$0.26 | -$0.25 | +3.9% | $0.00B | $0.00B | -15.6% |
| — Q4 FY2024 | Nov 12, 2024 | -$0.21 | -$0.21 | +0.0% | $0.00B | $0.00B | +26.0% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.29
EPS Surpr.
+13.8%
Revenue
$0.00B
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.51
EPS Est.
-$0.37
EPS Surpr.
-37.8%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.33
EPS Surpr.
-6.1%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.28
EPS Surpr.
+10.7%
Revenue
$0.00B
Q1 FY2025
Mar 26, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.26
EPS Surpr.
+3.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.21
EPS Est.
-$0.21
EPS Surpr.
+0.0%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.29 | $-0.29 | $-0.29 | 6 |
| Q3 FY2027 | $-0.29 | $-0.29 | $-0.29 | 3 |
| Q2 FY2027 | $-0.31 | $-0.31 | $-0.31 | 5 |
| Q1 FY2027 | $-0.30 | $-0.30 | $-0.30 | 3 |
| Q4 FY2026 | $-0.29 | $-0.29 | $-0.29 | 6 |
| Q3 FY2026 | $-0.30 | $-0.27 | $-0.22 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +13.8% | $3.76 | $3.88 | +3.19% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -37.8% | $5.00 | $5.22 | +4.40% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -6.1% | $2.19 | $2.22 | +1.37% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +0.0% | $3.98 | $3.81 | -4.27% |
| ▲ Q2 FY2025 | May 12, 2025 | +10.7% | $2.35 | $2.51 | +6.81% |
| ▲ Q1 FY2025 | Mar 26, 2025 | +3.9% | $2.47 | $2.27 | -8.10% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $11.09 | $10.67 | -3.79% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +19.1% | $12.02 | $12.09 | +0.58% |
Q2 FY2026+3.19%
Report Date
May 11, 2026
EPS Beat/Miss
+13.8%
Price Before
$3.76
Price After
$3.88
Q1 FY2026+4.40%
Report Date
Mar 16, 2026
EPS Beat/Miss
-37.8%
Price Before
$5.00
Price After
$5.22
Q4 FY2025+1.37%
Report Date
Nov 10, 2025
EPS Beat/Miss
-6.1%
Price Before
$2.19
Price After
$2.22
Q3 FY2025-4.27%
Report Date
Aug 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.98
Price After
$3.81
Q2 FY2025+6.81%
Report Date
May 12, 2025
EPS Beat/Miss
+10.7%
Price Before
$2.35
Price After
$2.51
Q1 FY2025-8.10%
Report Date
Mar 26, 2025
EPS Beat/Miss
+3.9%
Price Before
$2.47
Price After
$2.27
Q4 FY2024-3.79%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$11.09
Price After
$10.67
Q3 FY2024+0.58%
Report Date
Aug 12, 2024
EPS Beat/Miss
+19.1%
Price Before
$12.02
Price After
$12.09
Avg Beat Reaction-0.93%
Avg Miss Reaction+2.89%
Beat Rate6 / 8 quarters
Largest Move-8.10% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CATX ends December
Perspective Therapeutics, Inc. (CATX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.25 — beating the analyst consensus of $-0.29 by +13.8%. The next CATX earnings date is expected around September 1, 2026.
Each quarter, investors track CATX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CATX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CATX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CATX earnings · 5 questionsPerspective Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CATX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CATX historically reports after market close (AMC).
CATX earnings datewhen is CATX earningsCATX next earnings datewhen does CATX report earningsCATX earnings calendar
▸ Source: FMP · Perspective Therapeutics, Inc. SEC filings · US GAAP · Perspective Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026